Dental and Medical Problems

Dent Med Probl
Index Copernicus (ICV 2020) – 128.41
MEiN – 70 pts
CiteScore (2021) – 2.0
JCI – 0.5
Average rejection rate (2021) – 81.35%
ISSN 1644-387X (print)
ISSN 2300-9020 (online)
Periodicity – quarterly

Download PDF

Dental and Medical Problems

2019, vol. 56, nr 1, January-March, p. 105–110

doi: 10.17219/dmp/100507

Publication type: clinical case

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Treatment of the facial basal cell carcinoma with the use of photodynamic therapy: A case report

Leczenie ogniska raka podstawnokomórkowego skóry twarzy z użyciem terapii fotodynamicznej – opis przypadku

Mateusz Trafalski1,B,D, Klaudia Kazubowska2,C,D, Kamil Jurczyszyn1,A,F

1 Department of Oral Surgery, Faculty of Dentistry, Wrocław Medical University, Poland

2 Academic Dental Polyclinic in Wrocław, Poland


Basal cell carcinoma (BCC) is the most common skin cancer. It accounts for approx. 80% of human skin cancers and belongs to the group of non-melanoma skin cancers (NMSC). The highest incidence of this cancer is visible in older people, over 65 years of age. Photodynamic therapy (PDT) is a clinically approved method with a selective cytotoxic activity. It is used in the treatment of superficial forms of BCC, precancerous conditions (hyperkeratosis, actinic keratosis) and non-cancerous diseases (acne vulgaris, infection with herpes simplex virus – HSV, leukoplakia, lichen planus). The aim of the study was to apply PDT to a patient with a clinical diagnosis and histopathologically confirmed BCC. The patient, male, aged 82, reported to the Department of Oral Surgery at Wroclaw Medical University with BCC of dimensions 0.5 × 1.5 cm, present for 13 years in the area of the right mandibular angle, after previous surgical treatment. Photodynamic diagnosis (PDD) and PDT were employed using a semiconductor laser. 5-aminolevulinic acid (5-ALA) was used as a photosensitizer. The PDD and PDT procedures were applied at 2-week intervals for 3 months. Control visits after 3, 6 and 12 months did not show local recurrence. Photodynamic therapy is a highly useful, independent method of treating superficial forms of BCC.

Key words

basal cell carcinoma, photodynamic therapy, photodynamic diagnosis, aminolevulinic acid

Słowa kluczowe

rak podstawnokomórkowy, terapia fotodynamiczna, diagnostyka fotodynamiczna, kwas aminolewulinowy

References (26)

  1. Nejc D, Piekarski J, Pasz-Walczak G, Jeziorski A. Basal cell carcinoma of the skin – the young age of the patients causes diagnostic doubts [in Polish]. Onkol Pol. 2002;5(3–4):179–181.
  2. Yaghoobi R, Ranjbari N, Pazyar N, Foroozan M, Feily A. Basal cell carcinoma of vermilion mucosa of upper lip: A rare case report. Acta Med Indones. 2017;49(3):255–258.
  3. Loh T, Rubin AG, Brian Jiang SI. Management of mucosal basal cell carcinoma of the lip: An update and comprehensive review of the literature. Dermatol Surg. 2016;42(12):1313–1319.
  4. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994;73(2):328–335.
  5. Pabiańczyk R, Cieślik K, Tuleja T. Management methods of basal cell carcinoma [in Polish]. Chir Pol. 2011;13(1):48–58.
  6. Taub AF. A comparison of intense pulsed light, combination radiofrequency and intense pulsed light, and blue light in photodynamic therapy for acne vulgaris. J Drugs Dermatol. 2007;6(10):1010–1016.
  7. Tao JN, Duan SM, Li J. Experimental studies on treatment of HSV infections with photodynamic therapy using 5-aminolevulinic acid [in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007;21(1):79–82.
  8. Chen HM, Yu CH, Tu PC, Yeh CY, Tsai T, Chiang CP. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med. 2005;37(2):114–122.
  9. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, Fateh M, Djavid GE. Treatment of oral lichen planus with photodynamic therapy mediated methylene blue: A case report. Med Oral Patol Oral Cir Bucal. 2006;11(2):E126–E129.
  10. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23.
  11. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005;53(3):452–457.
  12. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: A prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149–1156.
  13. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol. 2004;151(1):141–147.
  14. Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: A randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol. 2013;69(2):280–287.
  15. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131–1136.
  16. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;24(1):CD003412.
  17. Williams HC, Bath-Hextall FJ, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–619.
  18. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomized controlled trial. Lancet Oncol. 2013;14(7):647–654.
  19. Romagosa R, Saap L, Givens M, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidylcholine as a transepidermal carrier. Dermatol Surg. 2000;26(4):338–340.
  20. Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open label trial. Lancet Oncol. 2015;16(6):729–736.
  21. Rizzo JM, Segal RJ, Zeitouni NC. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther. 2018;21:58–62.
  22. Nakayama M, Tabuchi K, Nakamura Y, Hara A. Basal cell carcinoma of the head and neck. J Skin Cancer. 2011;2011:496910.
  23. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. Eur J Dermatol. 2008;18(5):547–553.
  24. August PJ. Cryotherapy of nonmelanoma skin cancer. Clin Dermatol. 1995;13(6):589–592.
  25. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45(5):489–498.
  26. Kim SA, Lee KS, Cho JW. Photodynamic therapy combined with cryotherapy for the treatment of nodular basal cell carcinoma. Oncol Lett. 2013;6(4):939–941.